Patents Issued in January 18, 2018
  • ADHESIVE PATCH
    Publication number: 20180015049
    Abstract: Disclosed is an adhesive patch having a support and an adhesive agent layer laminated on the support, wherein the support consists of spunlace nonwoven fabric, the adhesive agent layer comprises an SIS block copolymer and liquid paraffin, the adhesive patch has a first direction, which is a predetermined reference axis direction, and a second direction, which is orthogonal to the first direction, and a bending resistance in the first direction of the adhesive patch is 18 to 30 mm.
    Type: Application
    Filed: February 5, 2016
    Publication date: January 18, 2018
    Inventors: Kentaro NAKASHIMA, Masahiro SATO, Yasuhisa KOSE, Takaaki YOSHINAGA
  • ANESTHETIC BANDAGE
    Publication number: 20180015050
    Abstract: A bandage for delivering an anesthetic through a patient's skin at the site of a hypodermic injection prior to the administration of the hypodermic injection to alleviate pain due to the injection.
    Type: Application
    Filed: July 18, 2017
    Publication date: January 18, 2018
    Inventor: Ana R. Olivero
  • MODULATORS OF ALPHA-DICARBONYL DETOXIFICATION AND THEIR USE FOR THE TREATMENT OF DIABETIC PATHOLOGIES
    Publication number: 20180015051
    Abstract: In various embodiments compositions and methods are provided for ameliorating a pathology characterized by elevated ?-dicarbonyl compounds or prophylactically slowing or stopping the onset of said pathology in a mammal. In certain embodiments the method comprises administering to the mammal an agent that activates TRPA1 in an amount sufficient to activate TRPA1, and/or to ameliorate one or more symptoms of the pathology (e.g., diabetes or a complication thereof), and/or to slow or stop the onset of the pathology, and/or to lower the level of ?-dicarbonyl compounds in the mammal.
    Type: Application
    Filed: July 12, 2017
    Publication date: January 18, 2018
    Inventors: PANKAJ KAPAHI, NEELANJAN BOSE, JYOTISKA CHAUDHURI
  • DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER NUCLEOSIDE ANALOGUES HAVING ANTI-CORONAVIRUS ACTIVITY
    Publication number: 20180015052
    Abstract: The present invention is directed to compounds, methods and compositions for treating or preventing viral infections using nucleosides analogs. Specifically, the present invention provides for the design and synthesis of acyclic fleximer nucleoside analogues having increased flexibility and ability to alter their conformation structures to provide increased antiviral activity potential with the result of inhibiting several coronaviruses.
    Type: Application
    Filed: January 28, 2016
    Publication date: January 18, 2018
    Inventors: KATHERINE L. RADTKE, HANNAH L. PETERS, JOHAN NEYTS, DIRK JOCHMANS, ERIC J. SNIJDER
  • STABLE TRIENTINE FORMULATIONS
    Publication number: 20180015053
    Abstract: Provided are pharmaceutical dosage forms comprising (i) trientine or a pharmaceutically acceptable salt of trientine, in a (ii) sealed packaging. The sealed packaging provides a high barrier protection against air, moisture and light and prevents exposure of the drug to conditions that facilitate its decomposition. The pharmaceutical dosage forms are useful for treating diseases or conditions where excess copper is not removed from the body, e.g., Wilson's disease.
    Type: Application
    Filed: February 3, 2016
    Publication date: January 18, 2018
    Inventor: Samuel D. Waksal
  • Method of Maintaining the Anti-Depressant Effect of Ketamine With Lithium
    Publication number: 20180015054
    Abstract: Disclosed herein is method for maintaining the anti-depressant effect of ketamine by administering lithium to patients that respond to ketamine treatment.
    Type: Application
    Filed: December 28, 2015
    Publication date: January 18, 2018
    Inventors: Dennis S. Charney, James Murrough
  • METHOD FOR SHORTENING ANTI-INFECTIVE THERAPY DURATION IN SUBJECTS WITH INFECTION
    Publication number: 20180015055
    Abstract: Methods of shortening the duration of anti-infective therapy and increasing the effectiveness of anti-infective drugs in subjects with infection are present. The methods are based on altering the replication rate of a pathogen, which makes the pathogen more susceptible to the actions of the anti-infective drug.
    Type: Application
    Filed: September 27, 2017
    Publication date: January 18, 2018
    Applicant: INSTITUTE FOR CLINICAL PHARMACODYNAMICS, INC.
    Inventor: Paul G. AMBROSE
  • PHARMACEUTICAL COMPOSITION FOR INHIBITING GROWTH OF CANCER STEM CELLS, CONTAINING ALDEHYDE INHIBITOR AND BIGUANIDE-BASED COMPOUND
    Publication number: 20180015056
    Abstract: The present invention relates to a pharmaceutical composition for inhibiting growth of cancer stem cells, containing an aldehyde inhibitor and a biguanide-based compound. The pharmaceutical composition according to the present invention contains a combination of an aldehyde inhibitor and a biguanide-based compound, which can effectively inhibit the growth of cancer stem cells such as neurospheres and can also inhibit the proliferation, invasion and metastasis of cancer cells, thereby preventing and/or treating cancer such as brain cancer.
    Type: Application
    Filed: February 2, 2016
    Publication date: January 18, 2018
    Inventors: Seok Gu KANG, Jong Hee CHANG, Eui Hyun KIM, Ji Hyun LEE, Yun Hee JO, Junseong PARK, Jin Kyoung SHIM, Soo Youl KIM
  • ERR ALPHA AND ERR GAMMA ARE ESSENTIAL COORDINATORS OF CARDIAC METABOLISM AND FUNCTION
    Publication number: 20180015057
    Abstract: Provided herein are methods and kits for increasing cardiac contraction, increasing mitochondrial activity, and/or increasing oxphos activity. Such methods include use of therapeutically effective amounts of one or more agents that increases estrogen-related receptor (ERR) ? activity and one or more agents that increases ERR? activity. In some examples, the method further includes administering a therapeutically effective amount of one or more agents that increases mitofusin 1 (Mfn1) activity.
    Type: Application
    Filed: September 19, 2017
    Publication date: January 18, 2018
    Applicant: Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Liming Pei, Michael Downes, Ruth T. Yu, Annette Atkins
  • METHODS OF THERAPEUTIC MONITORING OF PHENYLACETIC ACID PRODRUGS
    Publication number: 20180015058
    Abstract: The present disclosure provides methods for adjusting the dosage of PAA prodrugs (e.g., HPN-100, PBA) based on measurement of PAA and PAGN in plasma and calculating the PAA:PAGN ratio so as to determine whether PAA to PAGN conversion is saturated.
    Type: Application
    Filed: August 25, 2017
    Publication date: January 18, 2018
    Inventors: Bruce SCHARSCHMIDT, Masoud MOKHTARANI
  • ALL-NATURAL ENTERIC SOFT CAPSULES
    Publication number: 20180015059
    Abstract: Described herein are soft capsules and enteric soft capsules comprising cationic Type A gelatin and acid insoluble enteric polymers. In particular, the compositions and methods for manufacturing all-natural enteric soft capsules comprising Type A gelatin and matrix fills are described. In one embodiment, the enteric soft capsules comprise active ingredients such as non-steroidal anti-inflammatory drugs (NSAIDs). In another embodiment, the enteric soft capsule comprises matrix fills of omega-3 fatty acids.
    Type: Application
    Filed: September 28, 2017
    Publication date: January 18, 2018
    Inventors: Yunhua HU, Martin PIEST, Qi FANG, Henricus M.G.M. van Duijnhoven
  • HEALING TOPICAL COMPOSITION
    Publication number: 20180015060
    Abstract: There are provided, inter alia, novel stabilized compositions for treating skin conditions wherein a therapeutically effective dosage of sulfur compound is applied which results in healing. The utilized dosage of sulfur compound results in a quicker breakdown of the virus capsid structure, resulting e.g., in faster healing. The dosing regimen to maintain the concentrations of the sulfur containing amino acid at the affected site also helps achieve quicker healing. The formulations and the methods are applicable to a variety of skin conditions including cold sores, herpes, genital herpes and shingles.
    Type: Application
    Filed: January 27, 2016
    Publication date: January 18, 2018
    Inventors: Melwyn Abreo, Carol McBride, Talal Sheena
  • ANTIMICROBIAL-ANTIBIOFILM COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20180015061
    Abstract: Compositions comprising chelating agents, metal ion salts, gelling agents or a buffer, antimicrobials, antibiofilm agents and a pH adjuster or a buffer for the prevention and treatment of wound infections and food-borne diseases involving bacterial biofilms are disclosed. The anti-infective properties of a composition include reduction or killing of anaerobic/aerobic/facultative gram-negative and gram-positive wound infection associated bacteria occurring in polymicrobial biofilms. The composition may be in the form of lotion, cream, ointment, dressing, bandage, rinse, soak, gel, spray, or other suitable forms, including certain devices. Additionally, the invention offers an efficient method of delivering the formulated composition containing one or two chelating agents or chelating agents alone or in combination with a metal ion salt using either a nanoparticle or other efficient delivery systems.
    Type: Application
    Filed: July 18, 2017
    Publication date: January 18, 2018
    Inventors: Purushottam V. Gawande, Karen Lovetri, Nandadeva Yakandawala, Gordon Froehlich, Srinivasa Madhyastha
  • PPAR-alpha Activator, Pharmaceutical Composition, Food and Drink, Food Additive, Supplement and Method of Manufacturing the Same
    Publication number: 20180015062
    Abstract: The invention provides a novel PPAR? activator, a pharmaceutical composition, a food or a drink, a food additive, a supplement and a method of producing these products. The PPAR? activator includes an extract of a koji that contains 9-hydroxy-10,12-octadecadienoic acid (9-HODE: 10E, 12E) or an active fraction of the extract, as an active ingredient.
    Type: Application
    Filed: February 2, 2016
    Publication date: January 18, 2018
    Inventors: Teruo KAWADA, Tsuyoshi GOTO, Haruya TAKAHASHI, Hsin-Yi CHI, Noriyoshi ICHIP, Keiji NAKATA
  • ANTIVIRAL TREATMENTS
    Publication number: 20180015063
    Abstract: The invention provides unit dosage forms, kits, and methods useful for treating viral infections.
    Type: Application
    Filed: September 25, 2017
    Publication date: January 18, 2018
    Inventors: Yarlagadda S BABU, Pooran Chand, Shanta Bantia, Shane Arnold, John Michael Kilpatrick
  • METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS
    Publication number: 20180015064
    Abstract: The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.
    Type: Application
    Filed: August 25, 2017
    Publication date: January 18, 2018
    Inventors: Bruce SCHARSCHMIDT, Masoud MOKHTARANI
  • METHODS OF TREATING UREA CYCLE DISORDERS
    Publication number: 20180015065
    Abstract: The present disclosure provides novel methods for determining an effective dosage of a PAA prodrug and for treating a UCD that incorporate body surface area and urinary PAGN concentration. The disclosure further provides novel methods for assessing compliance with PAA prodrug administration that incorporate urinary PAGN concentration, and the subject's current dosing regimen, BSA, or age. The disclosure further provides novel methods of treating a UCD in a subject in need thereof that incorporate urinary PAGN concentration, and the subject's current dosing regimen, BSA, and/or age.
    Type: Application
    Filed: August 25, 2017
    Publication date: January 18, 2018
    Inventors: Bruce SCHARSCHMIDT, Masoud MOKHTARANI
  • DRUG COMPLEXES COMPRISING ALPHA-FETOPROTEIN
    Publication number: 20180015066
    Abstract: Compositions which comprise a hydro-phobic taxane such as paclitaxel are produced by non-covalent complexing between the taxane and alpha-fetoprotein c at a ratio of about 4 moles of taxane per mole of AFP. The complexes are water soluble and suitable for injection. Uses of the compositions for treating a subject presenting with an AFP receptor positive and taxane responsive ease cell are also disclosed.
    Type: Application
    Filed: January 26, 2016
    Publication date: January 18, 2018
    Inventors: Lakshmi P. Kotra, Christopher J. Paige, Angelica M. Bello, Igor Sherman
  • COMBINATION THERAPIES
    Publication number: 20180015067
    Abstract: Provided herein are methods of treating and sensitizing cancer comprising administering a glycolytic inhibitor and an oxidative phosphorylation inhibitor.
    Type: Application
    Filed: February 1, 2016
    Publication date: January 18, 2018
    Inventors: Daniel P. GOLD, Miguel QUINTELA-FANDINO
  • LACTATE DEHYDROGENASE INHIBITOR AND ANTIEPILEPTIC DRUG CONTAINING THE SAME
    Publication number: 20180015068
    Abstract: The invention provides a lactate dehydrogenase inhibitor that makes it possible to suppress refractory epilepsy in which conventional antiepileptic drugs are ineffective, and an antiepileptic drug containing said inhibitor. The lactate dehydrogenase inhibitor of the invention contains a compound represented by formula (III); i.e., isosafrole or a compound having isosafrole as a scaffold, and the antiepileptic drug of the invention has these compounds as an active ingredient.
    Type: Application
    Filed: February 9, 2016
    Publication date: January 18, 2018
    Applicant: NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY
    Inventors: Tsuyoshi Inoue, Nagisa Sada
  • ENHANCING AUTOPHAGY OR INCREASING LONGEVITY BY ADMINISTRATION OF UROLITHINS OR PRECURSORS THEREOF
    Publication number: 20180015069
    Abstract: Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.
    Type: Application
    Filed: September 11, 2017
    Publication date: January 18, 2018
    Inventors: Christopher Rinsch, William Blanco-Bose, Bernard Schneider, Laurent Mouchiroud, Dongryeol Ryu, Penelope Andreux, Johan Auwerx
  • METHODS AND COMPOSITIONS FOR UPREGULATING ENDOGENOUS ANTIOXIDANT SYSTEMS
    Publication number: 20180015070
    Abstract: A nutritional supplement for reducing free radical damage is disclosed. The nutritional supplement includes a first vehicle comprising an upregulating compound mixture configured to upregulate an endogenous antioxidant system and an exogenous antioxidant mixture and a second vehicle comprising a mineral mixture. The upregulating compound mixture is configured to upregulate an endogenous antioxidant system to protect against free radical damage. The upregulating compound mixture includes alpha lipoic acid, resveratrol, curcumin, EGCG, Olivol®, rutin, quercetin, and hesperetin. The endogenous antioxidant system includes transcription factors such as Nrf2, NF-?B, PPAR?, PPAR?/?, and PPAR? that promote transcription of antioxidant genes.
    Type: Application
    Filed: July 6, 2017
    Publication date: January 18, 2018
    Inventors: Mark Brown, John Cuomo, Jeremy Tian
  • CO-ADMINISTRATION OF ATORVASTATIN AND ETHYL EICOSAPENTAENOIC ACID OR A DERIVATIVE THEREOF
    Publication number: 20180015071
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing triglycerides in a subject on atorvastatin therapy, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof
    Type: Application
    Filed: September 27, 2017
    Publication date: January 18, 2018
    Inventors: Rene Braeckman, William Stirtan, Paresh Soni
  • Tryptophan is a pro-drug for infectious diseases and cancers
    Publication number: 20180015072
    Abstract: The innovation provides compositions and methods for treating infectious diseases and cancers, wherein said, in vitro, in higher active TDO (tryptophan 2,3-dioxygenase) sick cells that include cancer and infectious cells, tryptophan is capable of transferring into kynurenine derives to induce cells apoptosis; in vivo, tryptophan will turn into indican. Indican is capable of competing phosphorylation in the subject, competitively inhibiting process to form GTP, ATP, dGTP, dATP, that are essential for DNA/RNA synthesis; inhibiting host or invading gene amplification, or interfere with PLK(polo like kinase) phosphorylation to trigger cell apoptosis. All these function can be used for clinic treatment for cancer and infectious diseases.
    Type: Application
    Filed: July 12, 2016
    Publication date: January 18, 2018
    Inventors: Zhifang Zhu, Jun Zhang, Jinming Li
  • COMPOSITIONS AND METHODS FOR TREATING CHRONIC URTICARIA
    Publication number: 20180015073
    Abstract: Disclosed herein are methods of treating conditions, which may be associated with elevated levels of mast cells, basophils, eosinophils, or a combination thereof, with a therapeutically effective amount of dexpramipexole or pharmaceutical acceptable salt thereof.
    Type: Application
    Filed: August 14, 2017
    Publication date: January 18, 2018
    Inventors: Michael E. BOZIK, Steven DWORETZKY
  • USE OF MTOR INHIBITORS TO PREVENT AND REGRESS EDHESIONS AND FIBROSIS
    Publication number: 20180015074
    Abstract: Embodiments of the disclosure include preventing or reducing adhesion between two tissues and/or organs in an individual subjected to a procedure and/or preventing or reducing one or more keloids in an individual subjected to a procedure by providing to the individual an effective amount of a composition comprising one or more inhibitors of an mTOR pathway no earlier than about 4 days following the procedure.
    Type: Application
    Filed: February 8, 2016
    Publication date: January 18, 2018
    Inventor: Dean L. KELLOGG
  • METHODS AND COMPOSITIONS FOR TREATMENT OF VENOUS MALFORMATION
    Publication number: 20180015075
    Abstract: Methods of treating venous malformation (VM) are described. The described methods may include the steps of administering an mTOR inhibitor and an ABL kinase inhibitor to an individual in need thereof. Articles of manufacture comprising a container and a composition comprising the actives used in the disclosed methods are also described.
    Type: Application
    Filed: July 14, 2017
    Publication date: January 18, 2018
    Inventors: Elisa Boscolo, Xian Li
  • METHODS OF INCREASING TONIC INHIBITION AND TREATING SECONDARY INSOMNIA
    Publication number: 20180015076
    Abstract: Methods of increasing tonic inhibition in a subject in need thereof, for example a subject with Fragile X syndrome or Angelman syndrome are disclosed. Methods of treating secondary insomnia in a subject with a neurodegenerative disease or disorder are also disclosed.
    Type: Application
    Filed: September 27, 2017
    Publication date: January 18, 2018
    Inventor: Matthew DURING
  • COMPOUNDS AND METHODS FOR TREATING HIV INFECTION
    Publication number: 20180015077
    Abstract: Provided herein, inter alia, are methods and compounds for treating an HIV infection.
    Type: Application
    Filed: July 12, 2017
    Publication date: January 18, 2018
    Inventors: Robert Nakamura, Mark Burlingame, Alan Frankel, Adam Renslo
  • STABILIZED LIQUID FORMULATIONS CONTAINING PICOSULFATE
    Publication number: 20180015078
    Abstract: Stable liquid formulations containing picosulfate and magnesium citrate are provided. The formulations are useful to treat constipation or for the clearance of the bowel prior to X-ray examination, endoscopy or surgery.
    Type: Application
    Filed: July 7, 2017
    Publication date: January 18, 2018
    Inventors: Alfred Chi-Yeh Liang, Nipul Ghanshyambhai Patel
  • THERAPEUTIC AGENT FOR BILE DUCT CANCER
    Publication number: 20180015079
    Abstract: The present invention provides a therapeutic agent for bile duct cancer comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: March 23, 2016
    Publication date: January 18, 2018
    Inventors: Tatsuhiro SHIBATA, Yasuhito ARAI, Kenichi NOMOTO, Tomio NAKAMURA, Akihiko TSURUOKA, Saori MIYANO
  • COMPOSITIONS AND METHODS FOR TREATMENT IN PARKINSON'S DISEASE PATIENTS
    Publication number: 20180015080
    Abstract: The invention provides dosage forms and methods for treating Parkinson's Disease, symptoms resulting from Parkinson's Disease, side effects resulting from treatment of Parkinson's Disease with other pharmaceutical agents, and reducing the progress of Parkinson's Disease. In various embodiments, the dosage forms and methods utilize nicotine and/or salts thereof for once daily administration resulting in four pulsatile releases following administration.
    Type: Application
    Filed: February 24, 2017
    Publication date: January 18, 2018
    Inventor: Ari AZHIR
  • Crenolanib for Treating FLT3 Mutated Proliferative Disorders
    Publication number: 20180015081
    Abstract: The present invention relates to the use of crenolanib, in a pharmaceutically acceptable salt form for the treatment of FLT3 mutated proliferative disorders driven by constitutively activated mutant FLT3, and to a method of treatment of warm-blooded animals, preferably humans, in which a therapeutically effective dose of crenolanib is administered to an animal suffering from said disease or condition:
    Type: Application
    Filed: September 26, 2017
    Publication date: January 18, 2018
    Inventor: Vinay K. Jain
  • 6-Alkynyl-pyridine Derivatives
    Publication number: 20180015082
    Abstract: 6-Alkynyl-pyridine of general formula (I) their use as SMAC mimetics, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer.
    Type: Application
    Filed: September 26, 2017
    Publication date: January 18, 2018
    Inventor: Ulrich REISER
  • PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES
    Publication number: 20180015083
    Abstract: Disclosed are compounds of Formula 1, or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.
    Type: Application
    Filed: September 27, 2017
    Publication date: January 18, 2018
    Inventors: John David Lawson, Mark Sabat, Nicholas Scorah, Christopher Smith, Phong H. Vu, Haixia Wang
  • Use of Flibanserin in the Treatment of Obesity
    Publication number: 20180015084
    Abstract: The invention relates to compositions for the treatment of obesity and related diseases comprising a) an active substance being not flibanserin, selected from the group consisting of active substances for the treatment of obesity and obesity related diseases and b) flibanserin, optionally in the form of pharmacologically acceptable acid addition salts thereof.
    Type: Application
    Filed: July 31, 2017
    Publication date: January 18, 2018
    Applicant: Sprout Pharmaceuticals, Inc.
    Inventors: Angelo Ceci, Marcus Schindler
  • CGRP Receptor Antagonists
    Publication number: 20180015085
    Abstract: The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.
    Type: Application
    Filed: September 25, 2017
    Publication date: January 18, 2018
    Inventors: John Andrew Christopher, Miles Stuart Congreve, Sarah Joanne Bucknell, Francesca Deflorian, Mark Pickworth, Jonathan Stephen Mason
  • PLASMODIAL SURFACE ANION CHANNEL INHIBITORS FOR THE TREATMENT OR PREVENTION OF MALARIA
    Publication number: 20180015086
    Abstract: The invention provides methods of treating or preventing malaria comprising administering to an animal an effective amount of a compound of formula I: Q—Y—R1—R2??(I), wherein Q, Y, R1, and R2 are as described herein. Methods of inhibiting a plasmodial surface anion channel of a parasite in an animal are also provided. The invention also provides pharmaceutical compositions comprising a compound represented by formula I in combination with any one or more compounds represented by formulas II, V, and VI. Use of the pharmaceutical compositions for treating or preventing malaria or for inhibiting a plasmodial surface anion channel in animals including humans are also provided. Also provided by the invention are clag3 amino acid sequences and related nucleic acids, vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions.
    Type: Application
    Filed: October 3, 2017
    Publication date: January 18, 2018
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventor: Sanjay A. Desai
  • CONJUGATES OF CEREBLON BINDING COMPOUNDS AND G12C MUTANT KRAS, HRAS OR NRAS PROTEIN MODULATING COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20180015087
    Abstract: Conjugates of a cereblon-binding compound and compounds having modulatory activity against G12C mutant KRAS, HRAS or NRAS G12C proteins are provided. Methods associated with preparation and use of such conjugates, pharmaceutical compositions comprising such conjugates and methods to modulate the activity of G12C mutant KRAS, HRAS or NRAS G12C proteins for treatment of disorders, such as cancer, are also provided.
    Type: Application
    Filed: July 13, 2017
    Publication date: January 18, 2018
    Inventors: Yi Liu, Liansheng Li, Pingda Ren
  • SITE SPECIFIC DOSING OF A BTK INHIBITOR
    Publication number: 20180015088
    Abstract: Disclosed herein are formulations and methods of site specific administration of Compound (I) or a pharmaceutically acceptable salt thereof. Compound (I) is a potent BTK inhibitor and hence can be useful for the treatment of diseases such as cancer, autoimmune, and inflammatory diseases.
    Type: Application
    Filed: December 23, 2015
    Publication date: January 18, 2018
    Inventors: Philip NUNN, Bret BERNER, Mohammad Reza MASJEDIZADEH
  • METHOD OF TREATING OR PREVENTION OF ATHEROTHROMBOTIC EVENTS IN PATIENTS WITH HISTORY OF MYOCARDIAL INFARCTION
    Publication number: 20180015089
    Abstract: The present disclosure relates to methods for reducing the rate of cardiovascular death, myocardial infarction, or stroke in a patient in recognized need thereof, comprising administering to the patient a pharmaceutical composition comprising 60 mg ticagrelor twice daily.
    Type: Application
    Filed: January 27, 2016
    Publication date: January 18, 2018
    Applicant: ASTRAZENECA AB
    Inventors: Lars Magnus ANDERSSON, Tomas Lars-Gunnar ANDERSSON, Olof Fredrik BENGTSSON, Hans Peter HELD, Garnet Edward HOWELLS, Eva Christina JENSEN, Robert STOREY
  • COMPOUNDS FOR ENHANCING PPARy EXPRESSION AND NUCLEAR TRANSLOCATION AND THERAPEUTIC USE THEREOF
    Publication number: 20180015090
    Abstract: The present invention relates to a novel type of PPAR? modulator having a pyrimido[5,4-d]pyrimidine main structure. The PPAR? modulator can enhance the expression and nuclear translocation of PPAR? in cells. The present invention also relates to a pharmaceutical composition comprising the PPAR? modulator of the invention encapsulated in a pharmaceutically acceptable cell-penetrating drug delivery system so that it can be directly delivered into cells. The present invention thus provides a method of preventing or treating PPAR?-related disorders or conditions comprising administering to a subject in need thereof a therapeutically effective amount of the PPAR? modulator of the invention or the pharmaceutical composition of the invention.
    Type: Application
    Filed: January 27, 2016
    Publication date: January 18, 2018
    Applicant: REALINN LIFE SCIENCE LIMITED
    Inventors: Jen Cheng LIN, Chun-Chieh LIN, Hsu-Tung LEE, Yu-Ming FAN, Jui-Chi TSAI, Ying-Chi DU
  • USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
    Publication number: 20180015091
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Application
    Filed: July 26, 2017
    Publication date: January 18, 2018
    Inventors: JOSEPH J. BUGGY, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • PHARMACEUTICAL COMBINATIONS
    Publication number: 20180015092
    Abstract: The disclosure relates to a pharmaceutical combination of a mdm2/4 inhibitor, namely (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one or (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one, and a cyclin dependent kinase 4/6 (CDK4/6) inhibitor 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide. In addition, the disclosure relates to a pharmaceutical combination product. The disclosure also relates to corresponding pharmaceutical formulations, uses and treatment methods comprising said mdm2/4 inhibitor or a cyclin dependent kinase 4/6 (CDK4/6) inhibitor.
    Type: Application
    Filed: August 23, 2017
    Publication date: January 18, 2018
    Inventors: Stephane Ferretti, Sebastien Jeay, Ensar Halilovic, Fang Li, Hui-Qin Wang
  • TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS
    Publication number: 20180015093
    Abstract: Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating cancers or hematologic disorders.
    Type: Application
    Filed: April 28, 2017
    Publication date: January 18, 2018
    Inventors: Howard M. Stern, Jeffrey L. Kutok
  • TREATMENT OF CROHN'S DISEASE WITH DELAYED-RELEASE 6-MERCAPTOPURINE
    Publication number: 20180015094
    Abstract: Methods of treating patients suffering from Crohn's disease or ulcerative colitis who did not experience a clinical response to previous thiopurine administration, or suffered side effects from previous thiopurine administration, by administering a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed. Methods of treating patients suffering from Crohn's disease or ulcerative colitis who are also being administered a steroid, 5-aminosalicylic acid, or an antibiotic by adjunctively administering a delayed release pharmaceutical composition comprising 6-mercaptopurine are also disclosed.
    Type: Application
    Filed: September 28, 2017
    Publication date: January 18, 2018
    Applicant: Teva Pharmaceutical Industries Ltd.
    Inventors: Brenda Kolatch, Anna Hotovely-Salomon
  • NUCLEOTIDE ANALOGS
    Publication number: 20180015095
    Abstract: Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and/or ameliorating a papillomavirus infection.
    Type: Application
    Filed: September 28, 2017
    Publication date: January 18, 2018
    Inventors: Karl Y. Hostetler, James R. Beadle, Nadejda Valiaeva
  • HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS
    Publication number: 20180015096
    Abstract: This invention is in the area of improved compounds and methods for treating selected cancers and hyperproliferative disorders.
    Type: Application
    Filed: September 22, 2017
    Publication date: January 18, 2018
    Applicant: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
  • CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES
    Publication number: 20180015097
    Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.
    Type: Application
    Filed: August 4, 2017
    Publication date: January 18, 2018
    Inventors: Jose AIGUADE BOSCH, Silvia Gual Roig, Maria Prat Quinones, Carlos Puig Duran
  • APILIMOD COMPOSITIONS AND METHODS FOR USING SAME
    Publication number: 20180015098
    Abstract: The present invention relates to methods for treating Charcot-Marie-Tooth Disease (CMT) with apilimod and related compositions and methods.
    Type: Application
    Filed: February 2, 2016
    Publication date: January 18, 2018
    Applicant: LAM Therapeutics, Inc.
    Inventors: Henri LICHENSTEIN, Jonathan M. ROTHBERG